Most Read Articles
3 days ago
Higher concentrations of infliximab postinduction appear to result in early and long-term favourable therapeutic outcomes in patients with fistulizing Crohn’s disease (CD), a study has found.

PyloBalance as an adjunct therapy in the treatment of H. pylori infections

17 Jul 2019
All Helicobacters are urease-positive, able to convert aminoacids and urea into ammonia to neutralize stomach acid, andhighly mobile – characteristics that help them invade the mucosallayer to evade the body’s immune response. Helicobacter pylori(H. pylori) is linked to peptic ulcer disease, chronic gastritis,gastric mucosa-associated lymphoid tissue lymphoma, andearly gastric cancer. The infection rate of H. pylori is over 80% indeveloping countries and 20–50% in industrialized nations, withover 4.4 billion people testing positive for the bacteria in 2015.1,2

Related MIMS Drugs

Editor's Recommendations
Most Read Articles
3 days ago
Higher concentrations of infliximab postinduction appear to result in early and long-term favourable therapeutic outcomes in patients with fistulizing Crohn’s disease (CD), a study has found.